First Controlled Human Dose-Finding Study of Kratom Leaf Finds Opioid-Like Effects at High Doses, No Serious Adverse Events

Why it matters

This is one of the first controlled human pharmacology studies of botanical kratom leaf, providing critical clinical data about its dose-dependent effects—information that regulators and clinicians have long lacked.

The big picture

Regulatory debate over kratom has been hampered by a near-total absence of controlled human trials. This pilot study used a rigorous double-blind design with recreational polydrug users, spanning five dose levels, and represents a significant step toward understanding kratom's abuse potential in humans.

Key findings

• No deaths or serious adverse events occurred across all five doses tested (1–12 grams)
• Pupillary constriction—a marker of opioid activity—appeared at doses of 3 grams or higher
• Only the highest dose (12 g) significantly increased ratings of "drug liking," "good effects," and "high"
• Somnolence, nausea, and vomiting were the most common side effects across all doses
• Alkaloid blood concentrations rose in an orderly, dose-related pattern across the five cohorts

What they say

"Kratom produced some opioid-like effects including pupillary constriction, and the 12 g dose produced effects commonly associated with drugs of abuse such as visual analog scale ratings of drug liking, good effects, and high," the authors wrote.

Bottom line

In the first rigorous controlled human study of botanical kratom leaf, opioid-like effects emerged only at high doses and no serious adverse events occurred—giving regulators their first clinical evidence base for risk assessment.